Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo CEO ousted by majority shareholder Novo Nordisk Foundation Foundation chair, ex-Novo CEO Sorensen returns as board observer CEO ouster follows US market setbacks, falling share price Search ...

Reuters reports that online weight loss company Noom will sell low-dose versions of Novo Nordisk's Wegovy. Compounding pharmacies like Noom have struggled to figure out how to sell GLP-1 weight ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up ...

Novo Nordisk and Septerna plan to create new obesity pills that target G protein-coupled receptors (GPCRs), including GLP-1, GIP, and glucagon. HealthDay News — Danish drugmaker Novo Nordisk is ...

Novo Nordisk A/S’ CEO exit raises governance questions, but continuity through internal succession likely limits strategic disruption. Valuation reset (~16.5x forward non-GAAP P/E) vs.

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that longtime CEO Lars Fruergaard ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership and board of directors. Per the press release, Lars Fruergaard ...

Drug maker Novo Nordisk (NVO) said on Friday that Lars Fruergaard Jørgensen will step down as CEO, sending shares down 4% in pre-market trading. Jørgensen, appointed CEO in January 2017 ...